GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Selling and Marketing Expense

NRX Pharmaceuticals (STU:B1Q) Selling and Marketing Expense : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. NRX Pharmaceuticals's Selling and Marketing Expense for the three months ended in Jun. 2024 was €0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

NRX Pharmaceuticals Selling and Marketing Expense Historical Data

The historical data trend for NRX Pharmaceuticals's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Selling and Marketing Expense Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Selling and Marketing Expense
- - - -

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NRX Pharmaceuticals Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NRX Pharmaceuticals Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Selling and Marketing Expense
Comparable Companies
VIRX PIRS ABIO CADL MRKR ENLV NCNA ORGS SRNEQ MTEM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
NRXP:USA
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
Website
https://nrxpharma.com
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals Headlines

No Headlines